WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD. The Company has been selected for an invited talk, two oral presentations and two poster presentations.
Details of Tome’s ASGCT presentations are as follows: Date: Thursday, May 9, 2024 Time: 12:00-7:00pm Session: Poster Session: Gene Targeting and Gene Correction New Technologies Abstract number: 1214 Title: L-PGI: a DNA Ligase Mediated Gene Editing System for Versatile and Precise Genomic Integration Presenter: Jenny Xie Other authors: A. Nan, C. Bartolome, S. Kumar, S. Halperin, M. Chickering, P. Grewal, L. Chavez and J.D. Finn Date: Thursday, May 9, 2024 Time: 4:15-4:30pm Session: Oral Abstract Session: Targeted Gene Insertion Abstract number: 193 Title: Large Serine Integrase Off-Target Discovery and Validation for Therapeutic Human Genome Editing Presenter: Dane Hazelbaker Other authors: J.B. Mehta, D. Santesmasses, C. McGinnis, T. Biondi, A.M. Bara, X. Liang, B. Estes, J. Xie, K. Molugu, C. Luo, J. Cochrane, S. Kumar, M.H. Bakalar, J. Wang, D.J. O'Connell, J.D. Finn Date: Thursday, May 9, 2024 Time: 4:45-5:00pm Session: Oral Abstract Session: Targeted Gene Insertion Abstract number: 195 Title: Programmable Genomic Integration in Induced Pluripotent Stem Cells and Hematopoietic Stem and Progenitor Cells Presenters: Ravindra Amunugama and Minggang Fang Other authors: K. Molugu, M.J. Kimaz, L. Herchenroder, A. Zieba, J. Wang, W. Wang, K. Zheng, J. Zhang, D. Harrison, S. Kumar, D. O’Connell, C. Luo and J.D. Finn Date: Friday, May 10, 2024 Time: 8:00-8:26am Session: Advances in Genome Editing: In Vivo Small Edits and the Promise of Large Insertions Title: Integrase-Mediated Programmable Genomic Integration (I-PGI) Presenter: Rahul Kakkar Date: Friday, May 10, 2024 Time: 12:00-7:00pm Session: Poster Session: Targeted Gene Insertion Abstract number: 1676 Title: Low RT-Based Fidelity in Mouse Hepatocytes: Challenges and Solutions Presenter: Maike Thamsen Dunyak Other authors: P. Hanna, A. Nan, M. O’Hara, R. Pokharel, J. Xie and J.D. Finn About Tome Tome Biosciences, Inc., is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies. Follow us on X @Tome_Bio and on LinkedIn. www.tome.bio. PGI™, I-PGI™ and L-PGI™ are brand names and technologies of Tome Biosciences, Inc. Contacts: For media: CG Life CGL.TomeBio@cglife.com For investors: Michelle Avery, PhD, SVP, Corporate Affairs investors@tome.bio
|